Abstract
Background
Currently, there are no reliable biomarkers to identify patients at high risk of treatment-related cardiotoxicity before initiation of chemotherapy. The aim of this study was to identify biomarkers for predicting asymptomatic decrease in left ventricular ejection fraction (LVEF) after doxorubicin (DOX)-based chemotherapy.
Methods
A total of 83 breast cancer patients were treated with DOX-based chemotherapy. LVEF was measured before initiation and after completion of therapy. Thirty-nine patients were randomly assigned to the biomarker discovery cohort in which 9 had asymptomatic LVEF reduction (> 10% absolute reduction) after completing the therapy. The remaining 44 patients were grouped into the biomarker validation cohort in which 10 experienced asymptomatic LVEF reduction. Baseline plasma samples from the discovery cohort were analyzed by the SOMAscan proteomic assays for biomarker discovery. Biomarkers were verified using Olink proteomic assays in the validation cohort. Predictive models were generated using partial least squares discriminant analysis.
Results
SOMAscan analysis for the biomarker discovery cohort revealed that baseline plasma levels of biglycan, carbonic anhydrase 6, cadherin-5, CD109, and thrombospondin-4 were higher, and cystatin-F was lower in the patients with asymptomatic LVEF reduction compared to those without. The levels of these proteins were verified in the validation cohort and associated with increased odds of asymptomatic LVEF reduction. Among the individual protein biomarkers, thrombospondin-4 achieved the highest accuracy of prediction for asymptomatic LVEF reduction (79.5% [95% CI, 64.7%-90.2%]). A predictive model using these 6 proteins, in combination with baseline LVEF, was able to predict asymptomatic LVEF reduction with a sensitivity of 80% (95% CI, 44.4%-97.5%), a specificity of 88% (95% CI, 72.5%-96.7%), and overall accuracy of 86% (95% CI, 72.6%-94.8%).
Conclusions
These biomarkers and the model are potential new tools for the prediction of DOX-based treatment-related cardiotoxicity and the stratification of breast cancer patients before the initiation of chemotherapy. However, large-scale multi-center validation studies are required.
Graphical abstract
Similar content being viewed by others
Abbreviations
- CA6:
-
Carbonic anhydrase 6
- CD109:
-
CD109 antigen
- cTnT:
-
Cardiac troponin T
- DOX:
-
Doxorubicin
- ER:
-
Estrogen receptor
- HER2:
-
Human epidermal growth factor receptor 2
- LVEF:
-
Left ventricular ejection fraction
- PLS-DA:
-
Partial least squares discriminant analysis
- PR:
-
Progesterone receptor
- TSP4:
-
Thrombospondin-4
Acknowledgements
JRD would like to acknowledge the support by an appointment to the ORISE Research Participation Program at the National Center for Toxicological Research (NCTR), U.S. FDA, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA/NCTR.
Disclaimer
This article reflects the views of the authors and does not necessarily reflect those of the U.S. Food and Drug Administration. Any mention of commercial products is for clarification only and is not intended as approval, endorsement, or recommendation.
Funding
This work was supported by the U.S. Food and Drug Administration (FDA) Office of Women’s Health, the FDA Chief Scientist Challenge Grant, and the Inter-Center funds from the FDA Center for Drug Evaluation and Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board (IRB) of the University of Arkansas for Medical Sciences (IRB# 130212) and the U.S. Food and Drug Administration IRB—Research Involving Human Subjects Committee (RIHSC# 14-033 T). Written informed consent was obtained from each patient.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yu, LR., Cao, Z., Wang, D. et al. Baseline proteomic biomarkers for predicting chemotherapy-induced cardiotoxicity in breast cancer patients. Cardio-Oncology (2026). https://doi.org/10.1186/s40959-026-00559-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40959-026-00559-y